Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, Goidts V, Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I.
Wang J, et al. Among authors: wang m.
J Clin Invest. 2017 Aug 1;127(8):3075-3089. doi: 10.1172/JCI89092. Epub 2017 Jul 24.
J Clin Invest. 2017.
PMID: 28737508
Free PMC article.
Retracted.